Indivior Entered into an Exclusive License Agreement with Alar to Develop and Commercialise ALA-1000 and Future Buprenorphine-Based LAI Product Candidates
Shots:
- Alar will receive $10M in addition to an initial $5M option fee made by Indivior in Q1 & is also eligible to receive an additional fee upon achievement of developmental, regulatory & commercial milestones
- Indivior gets an exclusive right globally to develop, manufacture & commercialize ALA-1000 (sustained-release LAI prodrug of buprenorphine) & Alar's future buprenorphine-based LAI product candidates (Ex- in China, Hong Kong, Taiwan & Macau)
- Alar has been issued composition of matter & formulation patents with 2037 and 2039 expiration dates for ALA-1000 which covers formulations of sustained-release buprenorphine. The single-ascending dose study results showed the safety, tolerability & sustained release profile of ALA-1000 over 12wks. for opioid use disorder
Ref: PR Newswire | Image: Indivior
Related News:- Indivior to Acquire Opiant Pharmaceuticals for ~$145M
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
